As an example, endogenous antibodies directed against HER2/neu receptor, identified in cancer patients (20–22), can suppress HER2 phosphorylation and downstream activation of ERK and inhibit the transformed phenotype of HER2-expressing tumor cells (23). This evidence concerns the gene ERBB2 and neoplasm.